Champions Oncology market cap CSBR
Share price times shares outstanding: what the whole company sells for, since 2011.
- Today, Nov 2, 2026
- $66.9M
- Highest close in our data
- $195M
- Sep 2018
Champions Oncology is worth $66.9M at the close on Nov 2, 2026, at $4.81 a share.
That is down 28% over the last year and down 51% over five years.
Its highest close in our data was $195M in Sep 2018.
Market cap over time
Year by year
| Year | End of year | Low | High | Change |
|---|---|---|---|---|
| 2026 so far | $66.9M | $65.4M | $101.5M | −31% |
| 2025 | $96.9M | $79.8M | $160.3M | −16% |
| 2024 | $115.4M | $54.4M | $115.4M | +51% |
| 2023 | $76.4M | $54.2M | $94.5M | +25% |
| 2022 | $61.1M | $60.7M | $128.1M | −46% |
| 2021 | $113M | $108.7M | $167.4M | −22% |
| 2020 | $144.3M | $60.6M | $168.9M | +61% |
| 2019 | $89.6M | $61.1M | $129.7M | −4% |
| 2018 | $93.7M | $37.6M | $195M | +120% |
| 2017 | $42.6M | $25.6M | $49.1M | +54% |
| 2016 | $27.7M | $16.2M | $35.6M | −11% |
| 2015 | $31.1M | $20.7M | $74.9M | +3% |
| 2014 | $30.1M | $24.7M | $80.2M | −62% |
| 2013 | $80.2M | $14.1M | $127M | +248% |
| 2012 | $23M | $12.7M | $35.2M | −35% |
| 2011 | $35.2M | $30.1M | $44M | n/a |
Against its peers
Companies in Healthcare nearest Champions Oncology's size, closest first, today.
| Company | Market cap |
|---|---|
| CSBRChampions Oncology | $66.9M |
| LFVNLifevantage | $73.5M |
| SPROSpero Therapeutics | $60.6M |
| APTAlpha Pro Tech | $56.3M |
| ICCCImmucell | $95.9M |
| KEQUKewaunee Scientific | $96.7M |
| ATNMActinium Pharmaceuticals | $45M |
| NEPHNephros | $35.2M |
| PDEXPro DEX | $184.5M |
| PLXProtalix BioTherapeutics | $206.3M |
| NATRNatures Sunshine Products | $211.5M |
| Peer median | $84.7M |
What the market cap tells you
Share price times shares outstanding: what the whole company sells for today.
Size, not quality. Large caps move slower and are covered more. That is all it tells you.
More on Champions Oncology
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.